Scientists make advance in cancer research

A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).
The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer.

But research published today in the American Heart Association's journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of tumours. Not least because the drugs targeting it cause minimal side effects compared to other drugs – which can cause bleeding in the gut and .

Tumours must recruit their own supply to grow beyond a very small size. The research team studied the cells that line () in mice, and in particular the role of a widely expressed protein called beta3-integrin.

Dr Stephen Robinson, from UEA's school of Biological Sciences, said: "This protein has been the focus of over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment.

"The most advanced of these drugs, however, has recently failed a phase III clinical trial to treat an aggressive form of . In line with other clinical work, patients respond to treatment for a short while but then their cancers escape the treatment.

"This research helps to explain why these very promising drugs aren't meeting with the success that was anticipated and it suggests a way forward - how to make them work better.

"We have shown how tumours continue to grow despite treatment which should block blood vessel recruitment. They modulate how they are recruiting their blood vessels by using a different pathway from the one that is being targeted. We have identified some molecular changes in endothelial cells that occur with long-term inhibition of beta3-integrin that might help the cells escape the beta3-integrin blockade.

"Our research also shows that timing is critical when targeting the protein beta3-integrin.

"Importantly, these findings have re-established the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be re-focused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist."

'Acute Depletion of Endothelial beta3-Integrin Transiently Inhibits Tumour Growth and Angiogenesis in Mice' is published in the journal Circulation Research.

add to favorites email to friend print save as pdf

Related Stories

Sticky blood protein yields clues to autism

Mar 04, 2008

Many children with autism have elevated blood levels of serotonin – a chemical with strong links to mood and anxiety. But what relevance this “hyperserotonemia” has for autism has remained a mystery.

Blocking beta1-integrin to treat cancer

Jun 06, 2007

Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in The EMBO Journal this week. Blocking the action of this protein could ...

Recommended for you

Cancer fear can impact screening uptake

3 hours ago

People who worry about cancer are more likely to want to get screened for colon cancer, but feeling uncomfortable at the thought of cancer makes them less likely to actually go for the test, finds new UCL-led ...

Elucidating the origin of MDR tuberculosis strains

6 hours ago

A study has focused on the evolutionary history of the mycobacterium that causes tuberculosis, and more specifically on the Beijing lineage associated with the spread of multidrug resistant forms of the disease ...

Mexico escalating the fight against breast cancer

7 hours ago

On Avenue San Fernando, a tree-lined street crowded with food stands, the new wing of Mexico's flagship cancer hospital gleams like a silver airplane. Barely a year old, the light-filled structure attached to the National ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.